<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "https://foliamedica.bg/nlm/tax-treatment-NS0.dtd">
<article xmlns:tp="http://www.plazi.org/taxpub" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">87</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:A116C711-4C18-5A38-8F1E-5E97753A8A64</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Folia Medica</journal-title>
        <abbrev-journal-title xml:lang="en">FM</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0204-8043</issn>
      <issn pub-type="epub">1314-2143</issn>
      <publisher>
        <publisher-name>Plovdiv Medical University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/folmed.68.e185886</article-id>
      <article-id pub-id-type="publisher-id">185886</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Dermatology</subject>
          <subject>Pharmacy</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Monitoring adverse drug reactions of isotretinoin: a prospective observational study</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Qasim</surname>
            <given-names>Qutaiba A.</given-names>
          </name>
          <email xlink:type="simple">qutaibaqasim71@gmail.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0001-9566-0850</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Hassan</surname>
            <given-names>Jubran K.</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-0813-5260</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kadhim</surname>
            <given-names>Kadhim Ali</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-4040-1808</uri>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Akeel Al-hussaniy</surname>
            <given-names>Hany</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-2647-8574</uri>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq</addr-line>
        <institution>Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah</institution>
        <addr-line content-type="city">Basrah</addr-line>
        <country>Iraq</country>
        <uri content-type="ror">https://ror.org/00840ea57</uri>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">Department of Clinical Pharmacy, College of Pharmacy, University of Basrah, Basrah, Iraq</addr-line>
        <institution>Department of Clinical Pharmacy, College of Pharmacy, University of Basrah</institution>
        <addr-line content-type="city">Basrah</addr-line>
        <country>Iraq</country>
        <uri content-type="ror">https://ror.org/00840ea57</uri>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">College of Medicine, University of Baghdad, Baghdad, Iraq</addr-line>
        <institution>College of Medicine, University of Baghdad</institution>
        <addr-line content-type="city">Baghdad</addr-line>
        <country>Iraq</country>
        <uri content-type="ror">https://ror.org/007f1da21</uri>
      </aff>
      <aff id="A4">
        <label>4</label>
        <addr-line content-type="verbatim">Department of Pharmacology, College of Pharmacy, Al-Nisour University, Baghdad, Iraq</addr-line>
        <institution>Department of Pharmacology, College of Pharmacy, Al-Nisour University</institution>
        <addr-line content-type="city">Baghdad</addr-line>
        <country>Iraq</country>
        <uri content-type="ror">https://ror.org/0183g0e10</uri>
      </aff>
      <aff id="A5">
        <label>5</label>
        <addr-line content-type="verbatim">Dr Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq</addr-line>
        <institution>Dr Hany Akeel Institute, Iraqi Medical Research Center</institution>
        <addr-line content-type="city">Baghdad</addr-line>
        <country>Iraq</country>
        <uri content-type="ror">https://ror.org/00eq7x759</uri>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p><bold>Corresponding author</bold>: Qutaiba Qasim, Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq; Email: <email xlink:type="simple">qutaibaqasim71@gmail.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>10</month>
        <year>2026</year>
      </pub-date>
      <volume>68</volume>
      <issue>5</issue>
      <elocation-id>e185886</elocation-id>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/4D25E34F-5B24-53C9-AD0C-FEDD380F59BC">4D25E34F-5B24-53C9-AD0C-FEDD380F59BC</uri>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>01</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>03</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Qutaiba A. Qasim, Jubran K. Hassan, Kadhim Ali Kadhim, Hany Akeel Al-hussaniy</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p><bold>Introduction</bold>: Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (<abbrev xlink:title="adverse drug reactions">ADRs</abbrev>).</p>
        <p><bold>Aim</bold>: To characterize the occurrence, pattern, and severity of isotretinoin-related <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency.</p>
        <p><bold>Patients and methods</bold>: This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne.</p>
        <p><bold>Results</bold>: Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day.</p>
        <p><bold>Conclusion</bold>: With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>acne vulgaris</kwd>
        <kwd>dermatology</kwd>
        <kwd>isotretinoin</kwd>
        <kwd>prospective studies</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="sec1">
        <title>Citation</title>
        <p>Qasim QA, Hassan JK, Kadhim KA, Al-hussaniy HA. Monitoring adverse drug reactions of isotretinoin: a prospective observational st udy. Folia Med (Plovdiv) 2026;68(5):е185886. <ext-link ext-link-type="doi" xlink:href="10.3897/folmed.68.e185886">doi: 10.3897/folmed.68.e185886</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="sec2">
      <title>Introduction</title>
      <p>Acne vulgaris is one of the most common skin diseases in the world; it is a long-lasting inflammation of the pilosebaceous unit. It is commonly marked by comedones, papules, pustules, and nodules and, in some cases, permanent scarring, particularly on the face, chest, and back.<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup> According to population-based studies and estimates of Global Burden of Disease, acne, according to the sources, has a significant proportion of adolescents and youthful adults, and lifetime occurrence of acne is up to 80-90 percent in cohorts, and there is an impressive number of cases into adulthood. Recent studies have highlighted its high psychosocial and quality-of-life (<abbrev xlink:title="quality-of-life">QoL</abbrev>) effect. The patients usually report levels of embarrassment, social withdrawal, and reduced self-esteem, including education and career issues. Lashti and colleagues conducted a recent review of the system and found that there is a constant impact of negative effects on health-related quality of life (<abbrev xlink:title="health-related quality of life">HRQoL</abbrev>) in acne on emotional, social, functional, and similar scales compared to other long-term health conditions.<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup> The fact that there is substantial research on observational studies confirms the hypothesis that a larger score in clinical severity is associated with poorer <abbrev xlink:title="health-related quality of life">HRQoL</abbrev> and more distress.<sup>[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
      <p>Acne has also been identified to cause mental health outcomes, including depression and anxiety, symptoms, and suicidal ideation. The existing clinical practice recommendations focus on the active acknowledgment of the psychological outcomes of the acne by clinicians, as the emergence of visible lesions on the face and other exposed areas can result in stigma, bullying, and body image disruption.<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup> When acne is poorly managed, it may cause permanent scars and post-inflammatory dyspigmentation, and this may continue to propagate psychosocial impairment even after the active inflammation has healed.<sup>[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]</sup></p>
      <p>Even though isotretinoin has been widely used clinically for several decades, and the key adverse effects are well known, there are still significant gaps in understanding how reactions are measured and managed in the daily dermatology clinic. In large parts, the safety data is obtained from clinical trials or highly selected cohorts that adhere to stringent inclusion criteria and a schedule-based protocol in the laboratory.<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup> These circumstances are unlikely to be realistic in practice, where patients will vary in their adherence, present with a range of comorbidities, and have variable access to follow-up.<sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup> The current pharmacovigilance studies and regulatory evaluations have indicated that the issues persist, especially when it comes to pregnancy prevention, wherein, in certain countries, even with well-established PPPs, isotretinoin-exposed pregnancies are still reported.<sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup></p>
      <p>Meanwhile, a shift in prescribing is also taking place, with low-dose regimens, treatment of wider age groups, and the delivery of isotretinoin in non-hospital and home-based dermatology on the increase.<sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup> The number of current, clinic-based, observational studies that thoroughly outline the frequency, pattern, and severity of isotretinoin-related adverse responses and assess the extent to which recommended monitoring guidelines, including routine laboratory examinations, counseling documentation, and pregnancy counselling measures, are adhered to in practice is less than one might expect.<sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup> These lapses become particularly glaring in low- and medium-income regions as well as in health systems with immature pharmacovigilance. Standardized and higher-quality data on daily dermatology cases are therefore needed to influence local practice guidelines, develop surveillance mechanisms, and assume a more secure method of using isotretinoin.<sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup></p>
      <p>Acne vulgaris is a widespread chronic condition having serious physical and psychosocial consequences. Another important treatment regimen that the patients with moderate-to-severe disease or treatment-resistant disease should consider is systemic isotretinoin. Long-term remission is possible, and scarring can be eliminated.<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup> Nevertheless, isotretinoin is linked to a complicated range of adverse drug events, such as ubiquitous mucocutaneous alteration, which may be severe laboratory anomalies, severe teratogenicity, and musculoskeletal and potentially neuropsychiatric reactions.<sup>[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]</sup> Laboratory surveillance, pregnancy prevention, and clinical follow-up have been given comprehensive recommendations by the regulatory bodies and professional societies.<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup> Nevertheless, the evidence presented shows that these guidelines are not always adhered to in the everyday practice of dermatology, and isotretinoin-exposed pregnancies and other avoidable and unwanted results still happen.<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup></p>
    </sec>
    <sec sec-type="Aim" id="sec3">
      <title>Aim</title>
      <p>The current study aimed to assess the frequency and pattern of adverse drug reactions associated with isotretinoin therapy in dermatology clinics; evaluate the severity of isotretinoin-related adverse drug reactions using standardized assessment criteria; identify patient- and treatment-related risk factors for adverse drug reactions, including age, sex, comorbidities, concomitant drugs, daily dose, and cumulative dose; and assess adherence to recommended clinical and laboratory monitoring during isotretinoin therapy in participating dermatology clinics, including baseline and follow-up investigations, documentation of patient counseling, and pregnancy prevention measures where applicable.</p>
    </sec>
    <sec sec-type="Patients and methods" id="sec4">
      <title>Patients and methods</title>
      <sec sec-type="Study design and setting" id="sec5">
        <title>Study design and setting</title>
        <p>The study was a prospective observational cohort conducted in outpatient dermatology clinics in Basra. The primary purpose was to observe and describe adverse drug reactions (<abbrev xlink:title="adverse drug reactions">ADRs</abbrev>) in patients treated with systemic isotretinoin for acne.<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup> Two outpatient dermatology clinics in Basra, Iraq, conducted the study. These clinics are referral centers for moderate-to-severe acne from primary and secondary health facilities and also offer specialized acne treatment, including isotretinoin. The research period was from January 2024 to December 2025, enabling the incorporation of new courses on isotretinoin into the study and allowing 6 months as the minimum follow-up period for most participants. The data were collected in clinic visits and, when needed, using structured telephone follow-up.</p>
      </sec>
      <sec sec-type="Inclusion and exclusion criteria" id="sec6">
        <title>Inclusion and exclusion criteria</title>
        <p>Eligibility screening of all consecutive patients enrolled in the study who presented to the participating dermatology clinics within the study period and were prescribed systemic isotretinoin to treat acne was done based on predefined criteria. The study also required the participants to have a clinical diagnosis of acne vulgaris that warrants systemic isotretinoin therapy, be age 12 years and above, have either just started on isotretinoin or be receiving treatment at the time of the study, and be willing and able to attend the scheduled follow-up visits. The patients were eliminated when they lacked incomplete or missing baseline clinical or laboratory data; had less than four weeks of isotretinoin therapy; were pregnant or breastfeeding at the time of the baseline; or used isotretinoin to treat something other than acne. The inclusion criteria were extremely liberal, and only patients who met all the requirements of inclusion and none of the exclusion criteria were eligible to participate.</p>
      </sec>
      <sec sec-type="Sampling and sample size" id="sec7">
        <title>Sampling and sample size</title>
        <p>The sampling method employed was a consecutive sampling design, in which all eligible patients were enrolled in the study. A single-proportion formula was used to estimate the target sample size, assuming a 50% prevalence of any ADR (to maximize the sample size in the event of uncertainty), a confidence level of 95%, and an error of 5%. The minimum required sample size was estimated at 384 patients, accounting for a 10% loss to follow-up, and a target of 420 patients was set to achieve the necessary power. During the study period, 420 patients were screened. Twenty patients were excluded due to missing records or not meeting the inclusion criteria, leaving a final cohort of 400 patients.</p>
      </sec>
      <sec sec-type="Data collection procedures" id="sec8">
        <title>Data collection procedures</title>
        <p>Data were collected using a standardized case report form (<abbrev xlink:title="case report form">CRF</abbrev>) developed for the study. Information was gathered from three primary sources: medical records and clinic files (including electronic health records where available), laboratory reports from private central laboratories, and patient interviews, which were conducted in person during scheduled visits and, if necessary, by phone. For each patient, data were collected at baseline (initiation or first documented visit on isotretinoin) and at follow-up visits typically scheduled every 4-8 weeks, in accordance with routine clinic practice. The grades of adverse drug reactions (<abbrev xlink:title="adverse drug reactions">ADRs</abbrev>) were rated on Common Terminology Criteria of Adverse Events (<abbrev xlink:title="Common Terminology Criteria of Adverse Events">CTCAE</abbrev>) version 5.0. The grading of events was done using this standardized system, with mild, moderate, and severe (Grade 1, Grade 2, and Grade 3) events.</p>
      </sec>
      <sec sec-type="Monitoring schedule" id="sec9">
        <title>Monitoring schedule</title>
        <p>Baseline assessment included a clear history and physical examination, assessment of acne severity, and collection of pertinent laboratory tests (liver function tests, fasting lipid profile, and <abbrev xlink:title="complete blood count">CBC</abbrev>). A negative pregnancy test result in women who had the potential to give birth had to be documented before starting isotretinoin and then periodically during treatment in accordance with local risk reduction measures.<sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup></p>
        <p>Generally, follow-ups were scheduled after every 4-8 weeks, and the clinicians noted new or persistent <abbrev xlink:title="adverse drug reactions">ADRs</abbrev>, comorbid medications, dose changes, and adherence. Laboratory tests were repeated every 8-12 weeks, or more often if clinically necessary (e.g., the presence of liver disease or lipid disorders).</p>
      </sec>
      <sec sec-type="Sample size calculation" id="sec10">
        <title>Sample size calculation</title>
        <p>The sample size was calculated to estimate the prevalence of any ADR among isotretinoin-treated patients with acceptable precision. Assuming an ADR prevalence (p) of 0.50 (conservative estimate to maximize sample size), a 95% confidence level (Z=1.96), and a margin of error (d) of 0.05, the initial sample size (n) was derived from the formula:</p>
        <p>Substituting the values:</p>
        <p>To account for an estimated 10% non-response or loss to follow-up, the adjusted sample size was:</p>
        <p>Given logistical considerations and anticipated patient flow, a target of 420 patients was deemed feasible. Ultimately, 400 patients provided complete baseline and follow-up data suitable for analysis <bold>(Table <xref ref-type="table" rid="T1">1</xref>)</bold>.</p>
        <table-wrap id="T1" position="float" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>Sample size assumptions and final cohort</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>Parameter</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Value</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Assumed prevalence of any ADR (p)</td>
                <td rowspan="1" colspan="1">50%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Confidence level</td>
                <td rowspan="1" colspan="1">95% (Z=1.96)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Margin of error (d)</td>
                <td rowspan="1" colspan="1">5%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Initial calculated sample size</td>
                <td rowspan="1" colspan="1">384</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Anticipated loss to follow-up</td>
                <td rowspan="1" colspan="1">10%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Target sample size</td>
                <td rowspan="1" colspan="1">420</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Final number of patients analyzed</td>
                <td rowspan="1" colspan="1">400</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec sec-type="Results" id="sec11">
      <title>Results</title>
      <sec sec-type="Baseline characteristics" id="sec12">
        <title>Baseline characteristics</title>
        <p>The patients who were screened during the study period were 420, receiving systemic isotretinoin to treat acne. Twenty patients were excluded: 12 because they lacked 10 weeks of baseline laboratory data, 5 because their isotretinoin treatment lasted less than 4 weeks, and 3 because isotretinoin was prescribed for non-acne indicators (e.g., rosacea and folliculitis). The analytic cohort that came last had 400 patients <bold>(Fig. <xref ref-type="fig" rid="F1">1</xref>)</bold>.</p>
        <fig id="F1">
          <object-id content-type="arpha">BAA0190A-A202-5643-9F20-726F7F911E58</object-id>
          <label>Figure 1.</label>
          <caption>
            <p>Flow diagram of patient selection and analysis.</p>
          </caption>
          <graphic xlink:href="foliamedica-68-5-e185886-g001.jpg" id="oo_1823669.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/1823669</uri>
          </graphic>
        </fig>
        <sec sec-type="Demographic and clinical profile" id="sec13">
          <title>
            <italic>Demographic and clinical profile</italic>
          </title>
          <p>The mean age of the cohort was 21.8±4.7 years (range 13–36 years). Just over half of the patients were female (55.0%, <italic>n</italic>=220). The majority had moderate or severe acne at baseline, and most had a disease duration longer than 2 years. Baseline demographic and clinical characteristics are summarized in <bold>Table <xref ref-type="table" rid="T2">2</xref></bold>.</p>
          <table-wrap id="T2" position="float" orientation="portrait">
            <label>Table 2.</label>
            <caption>
              <p>Baseline demographic and clinical characteristics (<italic>n</italic>=400)</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">
                    <bold>Characteristic</bold>
                  </td>
                  <td rowspan="1" colspan="1">
                    <bold>Value</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Age, years, mean ± SD</td>
                  <td rowspan="1" colspan="1">21.8±4.7</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Age group, n (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• 12–17 years</td>
                  <td rowspan="1" colspan="1">92 (23%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• 18–24 years</td>
                  <td rowspan="1" colspan="1">214 (53.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• ≥25 years</td>
                  <td rowspan="1" colspan="1">94 (23.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Sex, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Male</td>
                  <td rowspan="1" colspan="1">180 (45%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Female</td>
                  <td rowspan="1" colspan="1">220 (55% )</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Duration of acne, years, median (IQR)</td>
                  <td rowspan="1" colspan="1">3.0 (2.0–5.0)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Acne severity at baseline, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Mild</td>
                  <td rowspan="1" colspan="1">40 (10%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Moderate</td>
                  <td rowspan="1" colspan="1">232 (58%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Severe</td>
                  <td rowspan="1" colspan="1">128 (32%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Comorbidities, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Any documented comorbidity</td>
                  <td rowspan="1" colspan="1">86 (21.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Baseline dyslipidemia</td>
                  <td rowspan="1" colspan="1">52 (13%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Known liver disease</td>
                  <td rowspan="1" colspan="1">10 (2.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Psychiatric history</td>
                  <td rowspan="1" colspan="1">14 (3.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Other (e.g. PCOS, thyroid disease)</td>
                  <td rowspan="1" colspan="1">24 (6%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Concomitant medications, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Oral antibiotics (current/recent)</td>
                  <td rowspan="1" colspan="1">80 (20%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Hormonal therapy (females)</td>
                  <td rowspan="1" colspan="1">34 (8.5%)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec sec-type="Treatment characteristics" id="sec14">
          <title>
            <italic>Treatment characteristics</italic>
          </title>
          <p>Most patients were initiated on a daily dose of 0.4-0.7 mg/kg/day. The mean planned treatment duration was approximately 7 months, and the median cumulative dose approached 120 mg/kg. Treatment-related variables are presented in <bold>Table <xref ref-type="table" rid="T3">3</xref></bold>.</p>
          <table-wrap id="T3" position="float" orientation="portrait">
            <label>Table 3.</label>
            <caption>
              <p>Isotretinoin treatment characteristics (<italic>n</italic>=400)</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">
                    <bold>Treatment variable</bold>
                  </td>
                  <td rowspan="1" colspan="1">
                    <bold>Value</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Starting dose, mg/kg/day, mean ± SD</td>
                  <td rowspan="1" colspan="1">0.52±0.12</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Starting dose category, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• &lt;0.5 mg/kg/day</td>
                  <td rowspan="1" colspan="1">134 (33.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• 0.5–0.7 mg/kg/day</td>
                  <td rowspan="1" colspan="1">214 (53.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• &gt;0.7 mg/kg/day</td>
                  <td rowspan="1" colspan="1">52 (13%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Maximum daily dose, mg/kg/day, mean ± SD</td>
                  <td rowspan="1" colspan="1">0.63±0.15</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Planned treatment duration, months, median (IQR)</td>
                  <td rowspan="1" colspan="1">7.0 (6.0–8.0)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Actual treatment duration, months, median (IQR)</td>
                  <td rowspan="1" colspan="1">6.8 (5.5–8.0)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Cumulative dose, mg/kg, median (IQR)</td>
                  <td rowspan="1" colspan="1">118 (95–140)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Cumulative dose category, <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• &lt;100 mg/kg</td>
                  <td rowspan="1" colspan="1">132 (33%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• 100–149 mg/kg</td>
                  <td rowspan="1" colspan="1">198 (49.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• ≥150 mg/kg</td>
                  <td rowspan="1" colspan="1">70 (17.5%)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
      </sec>
      <sec sec-type="Overall incidence of adverse drug reactions" id="sec15">
        <title>Overall incidence of adverse drug reactions</title>
        <p>Of the 400 patients, 360 (90%) experienced at least one isotretinoin-related ADR during follow-up, while 40 (10%) had no documented ADR. Across the cohort, a total of 965 individual ADR events were recorded, reflecting that many patients experienced more than one reaction. Mucocutaneous <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> were the most common category, followed by laboratory abnormalities and systemic symptoms (mainly musculoskeletal). The overall incidence and distribution of <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> are summarized in <bold>Table <xref ref-type="table" rid="T4">4</xref></bold>.</p>
        <table-wrap id="T4" position="float" orientation="portrait">
          <label>Table 4.</label>
          <caption>
            <p>Incidence and distribution of adverse drug reactions (n=400 patients; 965 ADR events)</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>Measure</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Value</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Patients with ≥1 ADR, <bold><italic>n</italic></bold> (%)</td>
                <td rowspan="1" colspan="1">360 (90%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Patients without ADR, <bold><italic>n</italic></bold> (%)</td>
                <td rowspan="1" colspan="1">40 (10%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Total ADR events, <italic>n</italic></td>
                <td rowspan="1" colspan="1">965</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="2">
                  <bold>ADR events by category, <italic>n</italic> (%)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Mucocutaneous</td>
                <td rowspan="1" colspan="1">730 (75.6%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Laboratory abnormalities</td>
                <td rowspan="1" colspan="1">115 (11.9%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Musculoskeletal</td>
                <td rowspan="1" colspan="1">75 (7.8%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Psychiatric</td>
                <td rowspan="1" colspan="1">20 (2.1%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Gastrointestinal</td>
                <td rowspan="1" colspan="1">15 (1.6%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">• Other (e.g. epistaxis not otherwise coded)</td>
                <td rowspan="1" colspan="1">10 (1%)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec sec-type="Pattern of specific adverse drug reactions" id="sec16">
        <title>Pattern of specific adverse drug reactions</title>
        <sec sec-type="Mucocutaneous ADRs" id="sec17">
          <title>
            <italic>Mucocutaneous ADRs</italic>
          </title>
          <p>Mucocutaneous <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> occurred in 354 patients (88.5%) and accounted for three-quarters of all recorded events. The most frequently observed were cheilitis and xerosis. The median time to onset of the first mucocutaneous ADR was 4 weeks (interquartile range 3–6 weeks) after starting isotretinoin <bold>(Table <xref ref-type="table" rid="T5">5</xref>)</bold>.</p>
          <table-wrap id="T5" position="float" orientation="portrait">
            <label>Table 5.</label>
            <caption>
              <p>Mucocutaneous adverse drug reactions (per patient, <italic>n</italic>=400)</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">
                    <bold>Mucocutaneous ADR</bold>
                  </td>
                  <td rowspan="1" colspan="1">
                    <bold>Patients affected <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Cheilitis (dry, cracked lips)</td>
                  <td rowspan="1" colspan="1">344 (86%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Xerosis of face / body</td>
                  <td rowspan="1" colspan="1">296 (74%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Lip fissuring / eczema</td>
                  <td rowspan="1" colspan="1">160 (40%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Facial erythema/dermatitis</td>
                  <td rowspan="1" colspan="1">80 (20%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Dry eyes / conjunctival irritation</td>
                  <td rowspan="1" colspan="1">120 (30%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Epistaxis (nasal dryness / bleeding)</td>
                  <td rowspan="1" colspan="1">104 (26%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Hair thinning / telogen effluvium</td>
                  <td rowspan="1" colspan="1">60 (15%)</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>Most mucocutaneous reactions were graded as mild to moderate. Almost all patients were managed conservatively with intensive use of emollients, lip balms, and artificial tears. Dose reduction due to mucocutaneous toxicity alone was required in 52 patients (13%), and only 4 patients (1%) discontinued treatment permanently due to severe, intolerable mucocutaneous symptoms (e.g., painful fissuring, eczematous dermatitis not controlled with topical therapy) <bold>(Figs <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref>)</bold>.</p>
          <fig id="F2">
            <object-id content-type="arpha">C338A512-6F1B-53C1-AEA1-1CBC4FF0A36A</object-id>
            <label>Figure 2.</label>
            <caption>
              <p>Representative mucocutaneous adverse drug reactions observed during isotretinoin therapy. Panel <bold>A</bold> illustrates cheilitis with fissuring and scaling of the lips, while panel <bold>B</bold> shows facial xerosis with mild erythema. These findings represent the most frequently documented adverse effects in the study cohort. Images are anonymized and published with patient consent.</p>
            </caption>
            <graphic xlink:href="foliamedica-68-5-e185886-g002.jpg" id="oo_1823670.jpg">
              <uri content-type="original_file">https://binary.pensoft.net/fig/1823670</uri>
            </graphic>
          </fig>
          <fig id="F3">
            <object-id content-type="arpha">209A781D-9E22-5C18-BE72-7FF87B9400BA</object-id>
            <label>Figure 3.</label>
            <caption>
              <p>Ocular and nasal mucosal dryness associated with isotretinoin therapy, commonly presenting within the first weeks of treatment.</p>
            </caption>
            <graphic xlink:href="foliamedica-68-5-e185886-g003.jpg" id="oo_1823671.jpg">
              <uri content-type="original_file">https://binary.pensoft.net/fig/1823671</uri>
            </graphic>
          </fig>
        </sec>
        <sec sec-type="Laboratory abnormalities" id="sec18">
          <title>
            <italic>Laboratory abnormalities</italic>
          </title>
          <p>Any treatment-emergent laboratory abnormality was documented in 88 patients (22%)—the most frequent changes involved serum triglycerides and liver enzymes. Many patients had overlapping abnormalities; therefore, the category totals exceed 22%. The distribution and severity of key laboratory abnormalities are shown in <bold>Table <xref ref-type="table" rid="T6">6</xref></bold>.</p>
          <table-wrap id="T6" position="float" orientation="portrait">
            <label>Table 6.</label>
            <caption>
              <p>Laboratory abnormalities during isotretinoin therapy (n=400)</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">
                    <bold>Laboratory parameter and grade</bold>
                  </td>
                  <td rowspan="1" colspan="1">
                    <bold>Patients <italic>n</italic> (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Triglycerides</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Mild elevation (≤2×<abbrev xlink:title="upper limit of normal">ULN</abbrev>)</td>
                  <td rowspan="1" colspan="1">52 (13%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Moderate elevation (&gt;2–3×<abbrev xlink:title="upper limit of normal">ULN</abbrev>)</td>
                  <td rowspan="1" colspan="1">16 (4%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Severe elevation (&gt;3×<abbrev xlink:title="upper limit of normal">ULN</abbrev>)</td>
                  <td rowspan="1" colspan="1">4 (1%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold>Total cholesterol</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Mild elevation</td>
                  <td rowspan="1" colspan="1">24 (6%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Moderate elevation</td>
                  <td rowspan="1" colspan="1">8 (2%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="2">
                    <bold><abbrev xlink:title="alanine aminotransferase">ALT</abbrev>/<abbrev xlink:title="aspartate aminotransferase">AST</abbrev></bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Mild elevation (≤3×<abbrev xlink:title="upper limit of normal">ULN</abbrev>)</td>
                  <td rowspan="1" colspan="1">18 (4.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">• Moderate elevation (&gt;3×<abbrev xlink:title="upper limit of normal">ULN</abbrev>)</td>
                  <td rowspan="1" colspan="1">6 (1.5%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1"><abbrev xlink:title="complete blood count">CBC</abbrev> abnormalities (e.g., leukopenia, thrombocytopenia)</td>
                  <td rowspan="1" colspan="1">6 (1.5%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p><abbrev xlink:title="upper limit of normal">ULN</abbrev>: upper limit of normal; <abbrev xlink:title="alanine aminotransferase">ALT</abbrev>: alanine aminotransferase; <abbrev xlink:title="aspartate aminotransferase">AST</abbrev>: aspartate aminotransferase; <abbrev xlink:title="complete blood count">CBC</abbrev>: complete blood count</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The majority of the abnormalities in the laboratory were asymptomatic and were identified during regular checks. Management involved dietary recommendations, increased laboratory monitoring, and some minor dose modifications for mild abnormalities. In 22 cases (5.5%), moderate increases in lipids or liver enzymes led to a temporary decrease in dose or temporary withdrawal of the treatment. Four individuals with moderate hypertriglyceridemia ( &gt;3×<abbrev xlink:title="upper limit of normal">ULN</abbrev>) and one with pronounced transaminitis were considered to have severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev>; isotretinoin was permanently discontinued in these individuals. None of the cases of clinically established acute pancreatitis were reported.</p>
        </sec>
        <sec sec-type="Systemic and other ADRs" id="sec19">
          <title>
            <italic>Systemic and other ADRs</italic>
          </title>
          <p>Systemic (primarily musculoskeletal and neurological) <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> occurred less frequently than mucocutaneous events but were clinically relevant in a subset of patients <bold>(Table <xref ref-type="table" rid="T7">7</xref>)</bold>.</p>
          <table-wrap id="T7" position="float" orientation="portrait">
            <label>Table 7.</label>
            <caption>
              <p>Systemic and other adverse drug reactions (<italic>n</italic>=400)</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">
                    <bold>Systemic/other ADR</bold>
                  </td>
                  <td rowspan="1" colspan="1">
                    <bold>Patients n (%)</bold>
                  </td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Low back pain</td>
                  <td rowspan="1" colspan="1">64 (16%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Generalized myalgia</td>
                  <td rowspan="1" colspan="1">52 (13%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Arthralgia (large or small joints)</td>
                  <td rowspan="1" colspan="1">40 (10%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Headache</td>
                  <td rowspan="1" colspan="1">36 (9%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Gastrointestinal symptoms (nausea, dyspepsia, abdominal discomfort)</td>
                  <td rowspan="1" colspan="1">24 (6%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Mood changes (e.g., low mood, irritability)</td>
                  <td rowspan="1" colspan="1">16 (4%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Clinically significant depressive symptoms*</td>
                  <td rowspan="1" colspan="1">3 (0.75%)</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">Other (e.g., photosensitivity, fatigue)</td>
                  <td rowspan="1" colspan="1">14 (3.5%)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>*Requiring psychiatric assessment and pharmacological intervention</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The majority of musculoskeletal complaints were mild or moderate and responded to simple analgesics and dose reduction. Isotretinoin use was temporarily interrupted in 12 patients (3.0%) due to musculoskeletal symptoms. Three of them had depressive symptoms of enough severity to justify psychiatric referral; in two cases, isotretinoin was stopped, and the symptoms got better in the next few weeks. There were no records of suicide attempts or psychotic outbursts.</p>
        </sec>
      </sec>
      <sec sec-type="Severity and causality assessment" id="sec20">
        <title>Severity and causality assessment</title>
        <p>At the patient level, 220 patients (55%) experienced only mild <abbrev xlink:title="adverse drug reactions">ADRs</abbrev>, 110 (27.5%) had at least one moderate ADR (with or without additional mild reactions), and 30 (7.5%) had at least one severe ADR during the course of therapy. The remaining 40 patients (10%) had no ADR. At the event level, the distribution of severity for the 965 ADR events is shown in <bold>Table 8</bold>.</p>
        <p>Causality assessment using the Naranjo scale and WHO–UMC criteria indicated that the majority of <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> were either definite or probable. A small number were deemed unlikely to be related to isotretinoin (e.g., intercurrent infections) and were excluded from specific analyses.</p>
        <table-wrap id="T8" position="float" orientation="portrait">
          <label>Table 8.</label>
          <caption>
            <p>Severity of adverse drug reactions (event-based, <italic>n</italic>=965)</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>Severity category</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>ADR events n (%)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Mild</td>
                <td rowspan="1" colspan="1">690 (71.5%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Moderate</td>
                <td rowspan="1" colspan="1">230 (23.8%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Severe</td>
                <td rowspan="1" colspan="1">45 (4.7%)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec sec-type="Factors associated with adverse drug reactions" id="sec21">
        <title>Factors associated with adverse drug reactions</title>
        <p>For risk factor analysis, patients were grouped according to whether they experienced at least one moderate or severe ADR (<italic>n</italic>=140) or only mild or no <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> (<italic>n</italic>=260). Baseline and treatment characteristics in these two groups are compared in <bold>Table <xref ref-type="table" rid="T9">9</xref></bold>.</p>
        <table-wrap id="T9" position="float" orientation="portrait">
          <label>Table 9.</label>
          <caption>
            <p>Comparison of patients with versus without moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev></p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>Variable</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Mild/none <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> (<italic>n</italic>=260)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> (<italic>n</italic>=140)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold><italic>p-</italic>value*</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age, years, mean ± SD</td>
                <td rowspan="1" colspan="1">21.3±4.6</td>
                <td rowspan="1" colspan="1">22.4±4.9</td>
                <td rowspan="1" colspan="1">0.064</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Female sex, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">128 (49.2)</td>
                <td rowspan="1" colspan="1">92 (65.7)</td>
                <td rowspan="1" colspan="1">0.002</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean ± SD</td>
                <td rowspan="1" colspan="1">24.1±3.6</td>
                <td rowspan="1" colspan="1">24.8±3.8</td>
                <td rowspan="1" colspan="1">0.102</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Severe acne at baseline, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">74 (28.5)</td>
                <td rowspan="1" colspan="1">54 (38.6)</td>
                <td rowspan="1" colspan="1">0.041</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Baseline dyslipidemia, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">24 (9.2)</td>
                <td rowspan="1" colspan="1">28 (20.0)</td>
                <td rowspan="1" colspan="1">0.004</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Psychiatric history, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">6 (2.3)</td>
                <td rowspan="1" colspan="1">8 (5.7)</td>
                <td rowspan="1" colspan="1">0.092</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Daily dose ≥0.5 mg/kg, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">152 (58.5)</td>
                <td rowspan="1" colspan="1">118 (84.3)</td>
                <td rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cumulative dose ≥120 mg/kg, <italic>n</italic> (%)</td>
                <td rowspan="1" colspan="1">116 (44.6)</td>
                <td rowspan="1" colspan="1">78 (55.7)</td>
                <td rowspan="1" colspan="1">0.040</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Treatment duration, months, median (IQR)</td>
                <td rowspan="1" colspan="1">6.5 (5.5–7.5)</td>
                <td rowspan="1" colspan="1">7.2 (6.0–8.5)</td>
                <td rowspan="1" colspan="1">0.018</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>*<italic>p</italic> values derived from chi-square/Fisher’s exact tests for categorical variables and t-test/Mann–Whitney U for continuous variables as appropriate.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>In multivariable logistic regression, the dependent variable was the occurrence of at least one moderate/severe ADR. Variables entered into the model included sex, age, acne severity, baseline dyslipidemia, a daily dose of ≥0.5 mg/kg, and a cumulative dose of ≥120 mg/kg. The final model is presented in <bold>Table <xref ref-type="table" rid="T10">10</xref></bold>.</p>
        <table-wrap id="T10" position="float" orientation="portrait">
          <label>Table 10.</label>
          <caption>
            <p>Multivariable logistic regression for predictors of moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> (<italic>n</italic>=400)</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>Predictor</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Adjusted OR</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>95% CI</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold><italic>p</italic>-value</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Female sex</td>
                <td rowspan="1" colspan="1">1.82</td>
                <td rowspan="1" colspan="1">1.15–2.88</td>
                <td rowspan="1" colspan="1">0.011</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Baseline dyslipidemia</td>
                <td rowspan="1" colspan="1">2.15</td>
                <td rowspan="1" colspan="1">1.18–3.91</td>
                <td rowspan="1" colspan="1">0.012</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Daily dose ≥0.5 mg/kg</td>
                <td rowspan="1" colspan="1">3.05</td>
                <td rowspan="1" colspan="1">1.85–5.02</td>
                <td rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Severe acne at baseline</td>
                <td rowspan="1" colspan="1">1.38</td>
                <td rowspan="1" colspan="1">0.87–2.21</td>
                <td rowspan="1" colspan="1">0.171</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cumulative dose ≥120 mg/kg</td>
                <td rowspan="1" colspan="1">1.27</td>
                <td rowspan="1" colspan="1">0.82–1.97</td>
                <td rowspan="1" colspan="1">0.282</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age (per 1-year increase)</td>
                <td rowspan="1" colspan="1">1.03</td>
                <td rowspan="1" colspan="1">0.99–1.07</td>
                <td rowspan="1" colspan="1">0.184</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The model demonstrated acceptable calibration (Hosmer–Lemeshow <italic>p</italic>=0.63), higher daily dose, female sex, and baseline dyslipidemia were independently associated with an increased risk of moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev>.</p>
      </sec>
      <sec sec-type="Impact on treatment and clinical outcomes" id="sec22">
        <title>Impact on treatment and clinical outcomes</title>
        <p>ADR-related modifications to isotretinoin therapy were common but did not prevent most patients from completing a clinically effective course. Based on the most intensive action taken, treatment modifications are summarized in <bold>Table <xref ref-type="table" rid="T11">11</xref> (Fig. <xref ref-type="fig" rid="F4">4</xref>)</bold>.</p>
        <fig id="F4">
          <object-id content-type="arpha">FD8D0F48-EE76-581C-B03C-159C005C3531</object-id>
          <label>Figure 4.</label>
          <caption>
            <p>Clinical response to isotretinoin therapy showing marked reduction in inflammatory acne lesions after six months of treatment.</p>
          </caption>
          <graphic xlink:href="foliamedica-68-5-e185886-g004.jpg" id="oo_1823672.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/1823672</uri>
          </graphic>
        </fig>
        <table-wrap id="T11" position="float" orientation="portrait">
          <label>Table 11.</label>
          <caption>
            <p>Impact of <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> on isotretinoin treatment (<italic>n</italic>=400)</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>ADR-related treatment modification</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Patients <italic>n</italic> (%)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">No ADR-related change</td>
                <td rowspan="1" colspan="1">266 (66.5%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dose reduction only</td>
                <td rowspan="1" colspan="1">90 (22.5%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Temporary interruption (with later restart)</td>
                <td rowspan="1" colspan="1">28 (7.0%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Permanent discontinuation due to ADR</td>
                <td rowspan="1" colspan="1">16 (4.0%)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Among the 16 patients who permanently discontinued isotretinoin due to <abbrev xlink:title="adverse drug reactions">ADRs</abbrev>, the main reasons were: severe laboratory abnormalities (<italic>n</italic>=8), severe refractory mucocutaneous symptoms (<italic>n</italic>=4), significant musculoskeletal pain (<italic>n</italic>=2), and clinically significant depression (<italic>n</italic>=2).</p>
        <p>Regarding clinical response, evaluation was available for 350 patients who completed at least 4 months of therapy; complete or near-complete clearance of acne lesions (≥90% reduction) was observed in 270/350 (77.1%). A good response (50%–89% reduction) occurred in 58/350 (16.6%), and a minimal response (&lt;50% reduction) was documented in 22/350 (6.3%).</p>
      </sec>
    </sec>
    <sec sec-type="Discussion" id="sec23">
      <title>Discussion</title>
      <p>The general incidence and trend of <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> among this group are similar to those reported in the literature worldwide.‌<sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup> The meta-analytic and systematic review data show that mucocutaneous alterations, in particular, cheilitis and xerosis, are nearly universal in patients taking isotretinoin since they typically occur in more than 80-90% of treated people.<sup>[<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B21">21</xref>]</sup> These frequencies (cheilitis 86%, xerosis 74%) are, in general, within this range and comparable to recent extensive real-world cohort studies in Europe and North America, in which mucocutaneous toxicity is the most consistent and predictable of all adverse-effect profiles of isotretinoin use.<sup>[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]</sup> The percentage of patients with any laboratory abnormality (22%) in Iraq is slightly higher than in particular Western series, where the clinical significance of lipid and liver enzyme increases is somewhat rare, and the results may not lead to any change.<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup> Our results are consistent with the results of other areas that reveal that the measurable biochemical alterations, particularly hypertriglyceridemia, and mild transaminitis are not uncommon when using isotretinoin and are more common in patients with existing metabolic risk factors.<sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup> Most importantly, in such reports, severe hepatotoxicity was uncommon and recovered on dose reduction or withdrawal.<sup>[<xref ref-type="bibr" rid="B25">25</xref>]</sup></p>
      <p>We also have similar rates of musculoskeletal symptoms and headache, which are also characterized by the literature of the time as low-grade back pain, arthralgia, and myalgia, which are frequent but generally mild complaints.<sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup> A recent meta-analysis of over 1.6 million study participants shows that the very low incidence of serious psychiatric outcomes in our cohort is consistent with no relative risk of suicide or psychiatric disorder among isotretinoin users compared with non-users and actually a decreased risk of suicide attempt at 2-4 years of follow-up.<sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup> Although reports of mood disturbance and suicidality at the individual level keep emerging<sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup>, available evidence to date does not favor avoidance of isotretinoin in patients with a baseline psychiatric risk but instead close observation of said risk factors.</p>
      <p>The current results also have significant clinical implications for the practice of dermatology in Iraqi clinics and other resource-limited settings. To begin with, the frequency of <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> is high, specifically mucocutaneous symptoms and non-trivial abnormal biochemistry rates, which justify structured, protocol-based monitoring rather than informal or less rigid follow-up.<sup>[<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]</sup> Metabolic status, liver disease, and psychiatric history must be systematically documented at baseline, and a regular lab test should be conducted within the initial 3 months of treatment, when most clinically significant abnormalities occur.<sup>[<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]</sup> Meanwhile, our data and outside sources strongly indicate that really serious toxicity is uncommon, which is why a more risk-stratified monitoring paradigm will not require testing in low-risk individuals and will concentrate resources on patients with baseline dyslipidemia, high doses, or other comorbidities.<sup>[<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]</sup></p>
      <p>Secondly, the independent correlations between moderate/severe <abbrev xlink:title="adverse drug reactions">ADRs</abbrev> and increased dose and persistently dyslipidemia indicate the relevance of dose individualization.‌<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup> In the case of obese patients with a history of metabolic syndrome or excessive lipids, low-dose isotretinoin should be used, with a progressive increase in dosage and accompanied by explicit lifestyle counseling, to decrease the number of adverse events but still attain satisfactory levels of acne control, which is supported by real-world studies of low-dose regimens.<sup>[<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B35">35</xref>]</sup> Integrating information on dose rationale, scheduled cumulative dose, and further modifications into clinical documentation would also be helpful for audit and continuous quality improvement.<sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup> Based on these results, several recommendations can improve pharmacovigilance and patient counseling regarding the use of isotretinoin in Iraq. At the service level, the use of a standardized isotretinoin monitoring checklist to measure baseline risk factors, lab tests, contraceptive counseling, mood screening, and ADR documentation would be beneficial for the dermatology practice. The addition of basic digital resources, such as SMS notifications for laboratory visits or follow-ups, might increase adherence to the monitoring regimen and reduce the risk of missed laboratory anomalies or undetected pregnancy.</p>
      <p>At the system level, creating a local registry or electronic prescribing module for isotretinoin, including mandatory fields for pregnancy testing and contraception among women of reproductive age, may reflect some of the most important aspects of European PPPs and provide real-world evidence to guide policy. To confirm this, larger, multicenter, prospective studies in Iraq and neighboring nations should be conducted in the future to establish the variation in regional patterns of ADR and the cost-effectiveness of various approaches to monitoring.<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup> Especially useful would be interventional studies that would test particular quality-improvement measures, i.e., structured checklists, electronic decision support, or specific laboratory protocols, as international evidence points to the fact that the currently used PPPs and monitoring practices are not yet perfect to prevent isotretinoin-related harm (Duran et al., 2023; Ivask et al., 2024). This would assist in aligning local practice with current global standards for the safe, effective, and patient-centered use of isotretinoin.</p>
      <p>The proposed study has the prospective design and a relatively large sample size (n=400), which offers a complete description of isotretinoin safety in the practice of Iraqi clinics. But a number of limitations need to be noted: the study was done in 2 clinics of one city; it might be an insufficient number of clinics to make generalizations about the results. Moreover, the use of patient recollection of some of these symptoms, like mood changes, and the fact that no control group is used are also weaknesses of observational studies.</p>
    </sec>
    <sec sec-type="Conclusion" id="sec24">
      <title>Conclusion</title>
      <p>This report provides a detailed literature review of the safety of oral isotretinoin in common dermatological practice in Iraq. Adverse drug reactions were frequently experienced in a cohort of 400 patients, although serious events were few and could be predicted. Mucocutaneous responses, particularly cheilitis and xerosis, were nearly universal, and laboratory abnormalities and musculoskeletal complaints were present in a significant minority but were mild and reversible. Women were more prone to clinically significant toxicity. Patients with baseline dyslipidemia and those receiving their daily dose of at least 0.5 mg/kg were prone to clinically substantial toxicity, and close attention to the choice of patients and the individualization of doses is essential. Although the rate of adverse effects is high, the majority of patients received therapy with satisfactory clinical responses and high levels of treatment compliance, demonstrating that isotretinoin remains a handy option when properly monitored. Nevertheless, the potential for avoidable toxicity points to a need for continuous improvement in current monitoring and counseling practices. Enhancing organized clinical and laboratory surveillance, integrating systematic pregnancy prevention tools, and incorporating routine standardization of adverse reactions into daily practice might provide a significant improvement in medication safety. These findings need multicenter studies to confirm them and help create context-specific national guidelines.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation>Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep 2020; 10:5754.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation>Layton AM, Bettoli V, Delore V, et al. The burden of acne vulgaris on health-related quality of life and psychosocial well-being domains: a systematic review. Am J Clin Dermatol 2025; 25(5):539–560.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation>Patel D, Thakre K, Badne P. Formulation and evaluation of <italic><tp:taxon-name><tp:taxon-name-part taxon-name-part-type="genus">Psidium</tp:taxon-name-part> <tp:taxon-name-part taxon-name-part-type="species">guajava</tp:taxon-name-part></tp:taxon-name></italic>-enriched antioxidant face mask for anti-aging skin care. Med Pharm J 2025; 4:174–86.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation>Malik A. Psycho-social evaluation of University of Chenab students for HRQoL based on Acne-Specific Quality of Life Questionnaire (Acne-QoL). Int J Clin Stud Med Case Rep 2024; 47.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation>Sarwer DB, Siminoff LA, Gardiner HM, Spitzer JC. The psychosocial burden of visible disfigurement following traumatic injury. Front Psychol 2022; 13:979574.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation>Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2024; 90:1006.e1–1006.e30.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation>Leung AK, Barankin B, Lam JM, et al. Dermatology: how to manage acne vulgaris. Drugs Context 2021; 10:1–18.</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation>Teichert M, Visser LE, Dufour M, et al. Isotretinoin use and compliance with the Dutch pregnancy prevention programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf 2010; 33:315–26.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74(5):945–73.e33.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation>Feszak IJ, Brzeziński P, Feszak S, et al. Isotretinoin treatment for acne vulgaris: a five-year retrospective analysis of clinical and biochemical adverse effects. J Clin Med 2025; 14:6473.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation>Rajput I, Anjankar VP. Side effects of treating acne vulgaris with isotretinoin: a systematic review. Cureus 2024;16(3):e55946. <ext-link ext-link-type="doi" xlink:href="10.7759/cureus.55946">doi: 10.7759/cureus.55946</ext-link>.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation>Ding RL, Zheng Y, Bu J. Physiological and psychological effects of isotretinoin in the treatment of patients with acne: a narrative review. Clin Cosmet Investig Dermatol 2023; 16:1843–54.</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation>Szilagyi DV, Tit DM, Judea-Pusta CT, et al. Real-world evidence of neuropsychiatric adverse reactions to isotretinoin: insights from EudraVigilance (2005–2025). Pharmaceuticals (Basel) 2025; 18:1252.</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation>Ruchitha S, Gupta N, Singh K. Exploring the multifaceted side effects of isotretinoin: a deep dive into case reports and observational studies. Arch Dermatol Res 2025; 317:499.</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation>Paljarvi T, McPherson T, Luciano S, et al. Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data. Br J Dermatol 2022; 187:64–72.</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation>Kapała J, Lewandowska J, Placek W, et al. Adverse events in isotretinoin therapy: a single-arm meta-analysis. Int J Environ Res Public Health 2022; 19:6463.</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation>Barbieri JS, Shin DB, Wang S, et al. The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol 2020; 82:72–9.</mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation>Lee KWA, Chan LKW, Lee CH, et al. Idiosyncratic reaction of isotretinoin: a review. Dermatol Rev 2024; 5:e70001.</mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation>Jha A, Shrestha R, Khadka A, et al. Effect of low-dose isotretinoin on lipid profile and liver enzymes in acne patients: a cross-sectional study. Nepal J Dermatol Venereol Leprol 2024; 22:28–31.</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation>Narayanan D, Rogge M. Cheilitis: a diagnostic algorithm and review of underlying etiologies. Dermatitis 2024; 35:431–42.</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation>Metin N, Karapınar T, Turan Ç. Lip mesotherapy with dexpanthenol in the treatment of isotretinoin-induced cheilitis. J Cosmet Dermatol 2022; 21:4684–90.</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation>Sibi Krishna T, Kaur R, Malhotra V, et al. The impact of isotretinoin on lipid profile: a systematic review. Ann Med Surg (Lond) 2025; 87:4395–403.</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation>Reyes-Hadsall S, Ju T, Keri JE. Use of oral supplements and topical adjuvants for isotretinoin-associated side effects: a narrative review. Skin Appendage Disord 2024; 10:1–9.</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation>Bazargan AS, Jafarzadeh A, Danandeh F, et al. Investigating metabolic syndrome markers and body mass index changes in patients with acne vulgaris treated with isotretinoin: a prospective study. J Cosmet Dermatol 2024; 23:4343–8.</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation>Tawanwongsri W, Kanchanasuwan T, Eden C. Isotretinoin and hepatotoxicity in patients with acne: a narrative review. Cosmetics (Basel) 2025; 12:17.</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation>Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol 2013; 54(3):157-62.</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation>Tan NKW, Tang A, MacAlevey NCYL, et al. Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis. JAMA Dermatol 2024; 160:54.</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation>Schaffer LC, Schaffer CB, Hunter S, et al. Psychiatric reactions to isotretinoin in patients with bipolar disorder. J Affect Disord 2010; 122:306–8.</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation>Patrzykąt KM, Puchalski K, Liszka P, et al. Beyond clinical efficacy: a literature review on the safety challenges of isotretinoin therapy. Qual Sport 2025; 48:67344.</mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation>Kaya K, Gevher Ö. Isotretinoin increases non-insulin-based surrogate markers of insulin resistance in acne vulgaris patients. Cutan Ocul Toxicol 2024; 43:410–5.</mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation>Turan Ç, Öner Ü. Lip mesotherapy with dexpanthenol as a novel approach to prevent isotretinoin-associated cheilitis. Dermatol Pract Concept 2023; e2023012.</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation>Landis MN. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, and relapse prevention. Am J Clin Dermatol 2020; 21(3):411–28.</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation>Paichitrojjana A, Paichitrojjana A. Oral isotretinoin and its uses in dermatology: a review. Drug Des Devel Ther 2023; 17:2573–91.</mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation>Muhaidat J, Alhuneafat L, Asfar R, et al. Exploring the incidence and risk factors of dyslipidemia in patients with severe acne vulgaris on systemic isotretinoin therapy: findings from a prospective study. Medicina (Kaunas) 2025; 61:439.</mixed-citation>
      </ref>
      <ref id="B35">
        <label>35.</label>
        <mixed-citation>Kandhari R. Isotretinoin: an updated review on the profile of its side-effects and their management. Egypt J Dermatol Venereol 2023; 43:1–7.</mixed-citation>
      </ref>
    </ref-list>
    <sec sec-type="Additional information" id="sec25">
      <title>Additional information</title>
      <sec sec-type="Ethical statement" id="sec26">
        <title>Ethical statement</title>
        <list list-type="bullet">
          <list-item>
            <p>The authors declared that no clinical trials were used in the present study.
</p>
          </list-item>
          <list-item>
            <p>The authors declared that no experiments on humans or human tissues were performed for the present study.
</p>
          </list-item>
          <list-item>
            <p>Written informed consent was obtained from all participants or their guardians for minors for anonymized patient information and publication of any accompanying images. The signed informed consent forms are safely deposited at the Iraqi Medical Research Center, Bagdad and are securely stored to protect patient privacy.
</p>
          </list-item>
          <list-item>
            <p>The study protocol was reviewed and approved by the Institutional Review Board of the College of Pharmacy at the University of Basra (Approval No. 238/2022). The study was conducted in accordance with the Declaration of Helsinki.
</p>
          </list-item>
          <list-item>
            <p>The authors declared that no experiments on animals were performed for the present study.
</p>
          </list-item>
          <list-item>
            <p>The authors declared that no commercially available immortalized human and animal cell lines were used in the present study.
</p>
          </list-item>
        </list>
      </sec>
      <sec sec-type="Conflict of interest" id="sec27">
        <title>Conflict of interest</title>
        <p>The authors declare no conflict of interest regarding the publication of this study.</p>
      </sec>
      <sec sec-type="Artificial Intelligence (AI) use" id="sec28">
        <title>Artificial Intelligence (AI) use</title>
        <p>The authors accept full responsibility for the content of the manuscript, including the disclosure of any use of AI. No AI tools were used in the preparation of this manuscript.</p>
      </sec>
      <sec sec-type="Funding" id="sec29">
        <title>Funding</title>
        <p>All authors declare that they received no financial support from any institution or university.</p>
      </sec>
      <sec sec-type="Author contributions" id="sec30">
        <title>Author contributions</title>
        <p>All authors have contributed equally.</p>
      </sec>
      <sec sec-type="Author ORCIDs" id="sec31">
        <title>Author ORCIDs</title>
        <p>Qutaiba Qasim <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-9566-0850">https://orcid.org/0000-0001-9566-0850</ext-link></p>
        <p>Jubran Hassan <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-0813-5260">https://orcid.org/0000-0003-0813-5260</ext-link></p>
        <p>Kadhim Ali Kadhim <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-4040-1808">https://orcid.org/0000-0002-4040-1808</ext-link></p>
        <p>Hany Akeel Al-hussaniy <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-2647-8574">https://orcid.org/0000-0003-2647-8574</ext-link></p>
      </sec>
      <sec sec-type="Data availability" id="sec32">
        <title>Data availability</title>
        <p>All data used are referenced or included in the article.</p>
      </sec>
    </sec>
  </back>
</article>
